Stocks · News reference
Humacyte Announces Publication Of One-Year V007 Phase 3 Results In The Lancet Digital Health Showing ATEV Superiority Over Autogenous Fistula For Hemodialysis Access
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Humacyte shares are trading higher after the company announced the publication of one-year Phase 3 results of its acellular tissue engineered vessel for hemodialysis access in The Lancet Digital Health.
Humacyte Announces Symvess Acellular Tissue Engineered Vessel-Tyod Now Being Used By Arizona Surgeons
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, today announced that Symvess, acellular tissue engineered vessel-tyod, is now being used by surgeons in